NEWS HIGHLIGHTSMedia Articles Related to Vigamox (Moxifloxacin)
Bacterial Conjunctivitis Drug Besivance Approved
Source: MedicineNet Pink Eye Specialty [2009.06.01]
Title: Bacterial Conjunctivitis Drug Besivance Approved
Category: Health News
Created: 6/1/2009
Last Editorial Review: 6/1/2009
Published Studies Related to Vigamox (Moxifloxacin)
Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. [2009.09]
OBJECTIVE: To compare the clinical and antimicrobial efficacy of besifloxacin ophthalmic suspension 0.6% with that of moxifloxacin ophthalmic solution 0.5% for the treatment of bacterial conjunctivitis. DESIGN: Multicenter, randomized, double-masked, parallel-group, active-controlled, noninferiority study. PARTICIPANTS: Patients 1 year of age or older with clinical manifestations of bacterial conjunctivitis... CONCLUSIONS: Besifloxacin ophthalmic suspension was non inferior to moxifloxacin ophthalmic suspension and provided similar safety and efficacy (clinical and microbiological) outcomes when used for the treatment of bacterial conjunctivitis. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. [2009.08.01]
RATIONALE: Moxifloxacin has potent activity against Mycobacterium tuberculosis in vitro and in a mouse model of antituberculosis (TB) chemotherapy, but data regarding its activity in humans are limited. OBJECTIVES: Our objective was to compare the antimicrobial activity and safety of moxifloxacin versus isoniazid during the first 8 weeks of combination therapy for pulmonary TB... CONCLUSIONS: Substitution of moxifloxacin for isoniazid resulted in a small but statistically nonsignificant increase in Week-8 culture negativity.
Electrocardiographic QTc changes due to moxifloxacin infusion. [2009.06]
Moxifloxacin (400-mg single dose) is a frequent positive control in thorough QT/QTc studies...
Pharmacokinetic, pharmacodynamic, and electrocardiographic effects of dapoxetine and moxifloxacin compared with placebo in healthy adult male subjects. [2009.06]
Selective serotonin reuptake inhibitors (SSRIs) may be associated with electrocardiographic effects. The electrocardiographic pharmacodynamics of dapoxetine, a short-acting SSRI being developed for the treatment of premature ejaculation, are compared with those of placebo and moxifloxacin (positive control) in 2 single-center, randomized, crossover studies in healthy men.
Period correction of the QTc of moxifloxacin with multiple predose baseline ECGs is the least variable of 4 methods tested. [2009.05]
This study compares 4 baseline correction methods on the effect of moxifloxacin on the QT/QTc interval: (1) day -1 time-matched baseline electrocardiograms (ECGs), (2) 3 triplicate predose ECGs, (3) 1 triplicate predose ECG, and (4) no baseline correction.Predose baseline methods (3 or 1 triplicate ECGs) are superior to the day -1 time-matched baseline correction or without baseline correction.
Clinical Trials Related to Vigamox (Moxifloxacin)
Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis [Completed]
Moxifloxacin, is being tested at approximately 60 study centres in 15 countries to determine
if this drug, when taken periodically in addition to the patients normal treatment, is
effective at reducing the number of flare-ups of chronic bronchitis he has. Approximately
1132 subjects will participate, and it is expected that the study will run for 2 years in
order to reach that goal. The patients individual involvement in the study will be 17
months. Moxifloxacin will be compared to a placebo drug (no active ingredients). The study
medication (moxifloxacin or placebo) will be taken in addition to the patients normal
medication for chronic bronchitis. In addition to the first clinic visit, called a screening
visit, the patient will be required to come back to the clinic for ten more study visits,
every 8 weeks. At the first visit the study co-ordinator will provide him with the dates for
all the visits. Over a period of 48 weeks the patient will return to the clinic on 6
occasions where he will receive the study medication which he will take for five days, in
addition to his normal treatment for chronic bronchitis. After this time the patient will
enter a follow up period for 24 weeks, where he will come to the clinic for assessments and
continue to take his normal medication but not receive the study drug. A complete medical
history will be taken at the first visit, including the patients past and current smoking
habit. A breath test will be performed to assess how well his lungs are functioning. In
addition, he will also be asked to provide a sputum sample for a microbiological examination
to identify any bacteria present in the sample. The patient must be able to provide a sputum
sample at the screening visit. If the patient meets all the inclusion / exclusion criteria
for the study, he will be allocated randomly to one of the following treatment groups at the
second visit.
- Treatment group 1: Receives moxifloxacin orally once daily for five days.
- Treatment group 2: Receives a matching placebo once daily for five days. In between each
visit (four weeks after your clinic visit), the study site co-ordinator will contact the
patient to check on his well being. If the patient or the doctor decides to stop the
patients participation in the trial for any reason, the patient will be required to
return to the clinic for a physical examination, take a breath test, provide a sputum
sample (if possible) and have a blood sample taken.
TBTC Study 27/28 PK: Moxifloxacin Pharmacokinetics During TB Treatment [Completed]
This substudy of TBTC Studies 27 and 28 compares 1) the pharmacokinetics of moxifloxacin
alone versus moxifloxacin administered with rifampin in healthy volunteers and 2) the
pharmacokinetics of moxifloxacin among patients with tuberculosis being treated with
multidrug therapy (isoniazid or ethambutol, rifampin, and pyrazinamide) to those of healthy
volunteers receiving moxifloxacin plus rifampin. It also evaluates the association between
polymorphisms of MDR1 genotype (P-glycoprotein) and rifampin pharmacokinetic parameters, the
effect of polymorphisms of MDR1 genotype and/or rifampin pharmacokinetics on isoniazid
pharmacokinetic parameters adjusted for N-acetyltransferase genotype (NAT2), and determines
by multivariate regression analyses the associations between moxifloxacin or rifampin
pharmacokinetic parameters and markers of tuberculosis disease severity including the
covariates of two-month culture positivity, cavitary lung disease, Body Mass Index, weight,
duration of study treatment prior to PK, co-morbidities and C-reactive protein. Healthy
volunteers and TB patients receive frequent scheduled blood draws during a 24 hour period
after ingesting a dose of TB drugs.
TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment [Active, not recruiting]
This double-blind, randomized controlled trial evaluates moxifloxacin versus isoniazid in
daily treatment during the first two months of treatment with rifampin, pyrazinamide and
ethambutol for sputum smear-positive pulmonary tuberculosis.
Efficacy and Safety of Sequential IV/PO Moxifloxacin in Comparison to IV Levofloxacin Plus IV Ceftriaxone Followed by PO Levofloxacin, in the Treatment of Patients With Community-Acquired Pneumonia [Completed]
Sequential therapy with intravenous to oral moxifloxacin, was tested at 69 study centres in
17 countries to determine if this treatment regimen is safe and effective in treating
hospitalized adult patients with community-acquired pneumonia. 748 patients were participated
in the study over an 18 months period. Individual patient involvement in the study was
approximately 4-6 weeks. Moxifloxacin was compared to a combination treatment regimen of high
dose intravenous ceftriaxone plus high dose intravenous levofloxacin followed by high dose
oral levofloxacin.
Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of the Ocular Surface After Loading Dose [Active, not recruiting]
The purpose of this study is to analyze the effect of Zymar and Vigamox on ocular surface
bacteria. We believe that Zymar will eradicate more ocular surface bacteria than Vigamox.
|
